{"id":9855,"date":"2024-04-18T15:55:32","date_gmt":"2024-04-18T13:55:32","guid":{"rendered":"https:\/\/www.geicogroup.com\/ensayos-clinicos\/"},"modified":"2025-11-26T11:16:28","modified_gmt":"2025-11-26T10:16:28","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/www.geicogroup.com\/en\/research\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"9855\" class=\"elementor elementor-9855 elementor-5761\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4db3e1c e-con-full e-flex e-con e-parent\" data-id=\"4db3e1c\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t<div class=\"elementor-element elementor-element-eb1eaea e-con-full e-flex e-con e-child\" data-id=\"eb1eaea\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-15d5445 elementor-widget-tablet__width-initial elementor-widget elementor-widget-heading\" data-id=\"15d5445\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Clinical Trials<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-fc0b133 e-con-full e-flex e-con e-parent\" data-id=\"fc0b133\" data-element_type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-dbd7433 e-con-full e-flex e-con e-child\" data-id=\"dbd7433\" data-element_type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-818e76b e-flex e-con-boxed e-con e-child\" data-id=\"818e76b\" data-element_type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-087ef2b elementor-widget elementor-widget-html\" data-id=\"087ef2b\" data-element_type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"w-100 d-flex flex-column parte_filtro\">\n    \n    <!--<a class=\"col-12 principales mb-3\" href=\"https:\/\/www.geicogroup.com\/investigacion\/investigacion-clinica\/ensayos-clinicos\/reclutamiento-abierto\/\">Abiertos<\/a>-->\n    \n    <div class=\"col-12 principales mb-3 d-flex flex-wrap justify-content-between align-items-center\">\n        <span class=\"col-8\">Open<\/span>\n        <button id=\"limpia_abiertos\" class=\"col-4\">\n            <svg width=\"30\" height=\"20\" viewBox=\"0 0 89 87\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n<path d=\"M72.386 64.3533C69.4669 65.0602 66.8328 65.7121 64.192 66.3341C60.997 67.0864 58.5584 64.9868 58.8093 61.7219C58.946 59.9434 60.1129 58.6595 62.1068 58.1772C66.3082 57.1615 70.5159 56.1717 74.7207 55.1697C76.2178 54.8131 77.7137 54.4499 79.2114 54.0947C81.782 53.4845 83.9805 54.8097 84.5964 57.3611C85.9797 63.0907 87.3583 68.8213 88.7239 74.5551C89.333 77.1126 88.1104 79.1812 85.6899 79.7521C83.1766 80.3452 81.189 79.0844 80.5515 76.4791C80.0163 74.2916 79.4956 72.1007 78.9284 69.7444C78.1053 70.6638 77.4191 71.4772 76.6844 72.244C66.8494 82.5077 54.8175 87.2589 40.6531 86.2065C21.3179 84.7701 4.738 69.9716 1.00025 51.0383C0.721494 49.6261 0.4856 48.1965 0.365418 46.7635C0.154507 44.2528 1.74423 42.341 4.11605 42.1132C6.43555 41.8905 8.35373 43.4316 8.65537 45.8957C9.58107 53.4617 12.3679 60.2263 17.5105 65.8791C25.3868 74.5367 35.2307 78.6111 46.936 77.8184C56.8798 77.1452 65.0706 72.8386 71.601 65.3366C71.8121 65.0938 72.0033 64.8337 72.3857 64.353L72.386 64.3533Z\"\/>\n<path d=\"M16.7059 21.7763C18.8492 21.2614 20.9736 20.7512 23.0979 20.2408C23.6712 20.103 24.2417 19.9523 24.8178 19.8292C27.1965 19.3211 29.2046 20.5976 29.795 22.9844C30.361 25.2719 29.1499 27.3681 26.8268 27.9866C24.7702 28.5341 22.6909 28.9946 20.6212 29.4919C16.9913 30.3642 13.3642 31.2481 9.73009 32.103C6.97247 32.7518 4.91754 31.5108 4.24693 28.7674C2.84761 23.0415 1.46328 17.3117 0.108136 11.575C-0.333935 9.70337 0.614901 7.8149 2.30613 6.96653C3.99658 6.11867 6.0828 6.51946 7.34091 7.92825C7.95181 8.61226 8.2261 9.44223 8.42965 10.3137C8.89644 12.3121 9.38006 14.3063 9.89393 16.4567C10.6111 15.6491 11.2241 14.9383 11.8589 14.2474C18.4553 7.06882 26.6758 2.88453 36.1337 0.820658C55.0917 -3.31656 82.3045 8.18597 87.8833 35.3987C88.1266 36.5848 88.2599 37.7934 88.4456 38.9913C88.8711 41.7347 87.5107 43.7802 85.0229 44.1371C82.3194 44.5247 80.4163 42.9515 80.0967 40.0745C79.6778 36.3005 78.754 32.649 77.1001 29.2318C71.3237 17.2969 61.8969 10.1354 48.7097 8.54126C36.125 7.01991 25.596 11.3836 17.1974 20.8748C17.0241 21.0705 16.8648 21.279 16.7101 21.4899C16.6812 21.5294 16.7059 21.608 16.7059 21.7763Z\"\/>\n<\/svg> \n        <\/button>\n    <\/div>\n    \n    <div class=\"col-12 d-flex flex-column justify-content-center align-items-center gap-3 my-3\">\n        \n        \n    <input type=\"radio\" class=\"btn-check filters-abiertos\" name=\"options\" id=\"option-reclutamiento\" autocomplete=\"off\" \/>\n  <label id=\"reclutamiento\" class=\"filter-type option-1\" for=\"option-reclutamiento\" data-mdb-ripple-init>Recruitment<\/label>\n\n  <input type=\"radio\" class=\"btn-check filters-abiertos\" name=\"options\" id=\"option-startup\" autocomplete=\"off\" \/>\n  \n  <!--<label class=\"filter-type option-2\" for=\"option-startup\" data-mdb-ripple-init>Start Up<\/label>-->\n\n    <input type=\"radio\" class=\"btn-check filters-abiertos\" name=\"options\" id=\"option-seguimiento\" autocomplete=\"off\" \/>\n    <label class=\"filter-type option-3\" for=\"option-seguimiento\" data-mdb-ripple-init>Follow - up<\/label>\n\n    <\/div>\n    \n    <div class=\"col-12 my-3 d-flex flex-column\">\n        <span class=\"titulo_filtro\">Ovary<\/span>\n        \n        <div class=\"col-12 secundarios mt-3\">\n            <div class=\"form-check\">\n              <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkOvario1\" \/>\n              <label class=\"form-check-label\" for=\"checkOvario1\">First-line<\/label>\n            <\/div>\n        <\/div>\n        \n        <div class=\"col-12 secundarios mt-3\">\n            <div class=\"form-check\">\n              <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkOvarioRecaida\" \/>\n              <label class=\"form-check-label\" for=\"checkOvarioRecaida\">Recurrence<\/label>\n            <\/div>\n        <\/div>\n        \n    <\/div>\n    \n    <div class=\"col-12 my-3 d-flex flex-column\">\n        <span class=\"titulo_filtro\">Cervix<\/span>\n        \n        <div class=\"col-12 secundarios mt-3\">\n            <div class=\"form-check\">\n              <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkCervixAvanzado\" \/>\n              <label class=\"form-check-label\" for=\"checkCervixAvanzado\">Locally advanced cervix<\/label>\n            <\/div>\n        <\/div>\n        \n        <div class=\"col-12 secundarios mt-3\">\n            <div class=\"form-check\">\n              <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkCervixMatastasico\" \/>\n              <label class=\"form-check-label\" for=\"checkCervixMatastasico\">Metastatic cervix<\/label>\n            <\/div>\n        <\/div>\n        \n    <\/div>\n    \n    <div class=\"col-12 my-3 d-flex flex-column\">\n        <span class=\"titulo_filtro\">Endometrium<\/span>\n        \n        <div class=\"col-12 secundarios mt-3\">\n            <div class=\"form-check\">\n              <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkEndometrioLocalizado\" \/>\n              <label class=\"form-check-label\" for=\"checkEndometrioLocalizado\">Localized<\/label>\n            <\/div>\n        <\/div>\n        \n        <div class=\"col-12 secundarios mt-3\">\n            <div class=\"form-check\">\n              <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkEndometrioAvanzado\" \/>\n              <label class=\"form-check-label\" for=\"checkEndometrioAvanzado\">Advanced<\/label>\n            <\/div>\n        <\/div>\n        \n    <\/div>\n    \n    <div class=\"col-12 my-3 d-flex flex-column\">\n        <span class=\"titulo_filtro\">Other<\/span>\n        \n        <div class=\"col-12 secundarios mt-3\">\n            <div class=\"form-check\">\n              <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkOtrosQuirurgico\" \/>\n              <label class=\"form-check-label\" for=\"checkOtrosQuirurgico\">Surgical<\/label>\n            <\/div>\n        <\/div>\n        \n    <\/div>\n    \n<\/div>\n<div class=\"w-100 d-flex flex-column parte_filtro\">\n    \n    <span class=\"col-12 close-cancel mb-3\">Closed | Cancelled<\/span>\n    \n    <div class=\"col-12 d-flex flex-wrap my-3 gap-2\">\n         <input type=\"radio\" class=\"btn-check filters-cerrados\" name=\"options_closed\" id=\"option-cerrado\" autocomplete=\"off\" \/>\n        <label class=\"filter-type option-4\" for=\"option-cerrado\" data-mdb-ripple-init>Closed<\/label>\n    \n        <input type=\"radio\" class=\"btn-check filters-cerrados\" name=\"options_closed\" id=\"option-cancelado\" autocomplete=\"off\" \/>\n        <label class=\"filter-type option-5\" for=\"option-cancelado\" data-mdb-ripple-init>Cancelled<\/label>\n    <\/div>\n    \n    <div class=\"col-12 secundarios mt-3\">\n        <div class=\"form-check\">\n          <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkCerradosOvario\" \/>\n          <label class=\"form-check-label\" for=\"checkCerradosOvario\">Ovarian cancer<\/label>\n        <\/div>\n    <\/div>\n    \n    <div class=\"col-12 secundarios mt-3\">\n        <div class=\"form-check\">\n          <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkCerradosCervix\" \/>\n          <label class=\"form-check-label\" for=\"checkCerradosCervix\">Cervical cancer<\/label>\n        <\/div>\n    <\/div>\n    \n    <div class=\"col-12 secundarios mt-3\">\n        <div class=\"form-check\">\n          <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkCerradosEndometrio\" \/>\n          <label class=\"form-check-label\" for=\"checkCerradosEndometrio\">Endometrial cancer<\/label>\n        <\/div>\n    <\/div>\n    <!--\n    <div class=\"col-12 secundarios mt-3\">\n        <div class=\"form-check\">\n          <input class=\"form-check-input\" type=\"checkbox\" value=\"\" id=\"checkCerradosQuirurgicos\" \/>\n          <label class=\"form-check-label\" for=\"checkCerradosQuirurgicos\">Quir\u00fargicos<\/label>\n        <\/div>\n    <\/div>-->\n    \n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-273a8f4 e-con-full e-flex e-con e-child\" data-id=\"273a8f4\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-947afdc elementor-widget elementor-widget-html\" data-id=\"947afdc\" data-element_type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"w-100 d-flex flex-column\" id=\"contenido_filtros\">\n    \n    <div id=\"contenidoOvario1\" class=\" col-12 d-flex justify-content-start flex-wrap abierto\">\n        \n        <!-- reclutamiento -->\n\n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n            \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    First - line\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov62\/GEICO 129-O\/N-Plus\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Purificaci\u00f3n Estevez\n                    <br>\n                    CoPI: Arantzazu Barquin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase III randomized, open label study of NiraParib maintenance after Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high-grade ovarian cancer patientS\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario 1\u00aa Linea\"\n                data-titulo=\"ENGOT-ov62\/GEICO 129-O\/N-Plus\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05460000\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n            \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    First - line\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-OV63\/GEICO 110-0\/NIRVANA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Randomized Study of Paclitaxel \u2013 Carboplatin followed by maintenance Niraparib versus Paclitaxel \u2013 Carboplatin \u2013 Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Following a Front-Line Complete Cytoreduction Surgery\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario 1\u00aa Linea\"\n                data-titulo=\"ENGOT-OV63\/GEICO 110-0\/NIRVANA\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-004278-76\/ES\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        \n        <!-- seguimiento -->\n        <!--<div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    First - line\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov45\/GEICO 74-O\/ATHENA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario 1\u00aa Linea\"\n                data-titulo=\"ENGOT-ov45\/GEICO 74-O\/ATHENA\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03522246\" target=\"_blank\">See more<\/a>\n        \n        <\/div>-->\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    First - line\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov46\/GEICO 76-O\/DUO-O\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: M\u00aa. Jes\u00fas Rubio\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario 1\u00aa Linea\"\n                data-titulo=\"ENGOT-ov46\/GEICO 76-O\/DUO-O\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03737643?rank=1\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    First - line\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov44\/GEICO 77-O\/FIRST\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Andr\u00e9s Redondo<br>\n                    CoPI: Lydia Gaba\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario 1\u00aa Linea\"\n                data-titulo=\"ENGOT-ov44\/GEICO 77-O\/FIRST\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03602859\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    First - line\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov43\/GEICO 80-O\/7339-001\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario 1\u00aa Linea\"\n                data-titulo=\"ENGOT-ov43\/GEICO 80-O\/7339-001\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03740165\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n    <\/div>\n    \n    <div id=\"contenidoOvarioRecaida\" class=\"mt-3 d-flex flex-wrap justify-content-start abierto\">\n        \n        <!-- reclutamiento -->\n\n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov76\/GEICO 127-O\/GLORIOSA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                    <br>\n                    CoPI: M\u00aa Jes\u00fas Bermejo\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Randomized Phase 3 Trial for Mirvetuximab + Bevatuximab manteinance in FR@High PSOC Patients\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT-ov76\/GEICO 127-O\/GLORIOSA\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05445778\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT gyn5\/GEICO 131-O\/NXP 800\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT gyn5\/GEICO 131-O\/NXP 800\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05226507?term=nxp800&rank=1\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <!--<div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT ov77\/GEICO XX-O\/REJOICE-ovarian 01\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Lydia Gaba\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 2\/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT ov77\/GEICO XX-O\/REJOICE-ovarian 01\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/search?term=NCT06161025\" target=\"_blank\">See more<\/a>\n        \n        <\/div>-->\n\n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n            \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov81\/GEICO 154-O\/RAMP 301\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator\u2019s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT-ov81\/GEICO 154-O\/RAMP 301\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05460000\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov84\/GEICO 141-O\/MK-2870-022\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer.\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT-ov84\/GEICO 141-O\/MK-2870-022\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06824467\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <!-- seguimiento -->\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 114-O\/ART0380C001\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                    <br>\n                    CoPI: Mar\u00eda Quind\u00f3s\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase I\/IIa, Open-label, Multi-center Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"GEICO 114-O\/ART0380C001\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04657068\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT ov72\/GEICO 122-O\/ROSELLA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator\u2019s choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT ov72\/GEICO 122-O\/ROSELLA\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/history\/NCT05257408?V_1=View\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov34\/GEICO 65-O\/AGO-OVAR 2.29\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Andr\u00e9s Redondo\n                    <br>\n                    CoPI: Pilar Barretina\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Atezolizumab in combination with Bevacizumab +\/- Chemotherapy versus Chemo-BEV standard in recurrent ovarian cancer \u2013 a randomised trial\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT-ov34\/GEICO 65-O\/AGO-OVAR 2.29\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/search?term=NCT03353831\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov41\/GEICO 69-O\/ANITA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT-ov41\/GEICO 69-O\/ANITA\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03598270\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov61\/GEICO 96-O\/EPIK-O\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Phase III, multi-center, randomized (1:1), open label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy (wPac or PLD), in participants with no germline BRCA mutation detected, platinum-resistant or refractory, HGSOC\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT-ov61\/GEICO 96-O\/EPIK-O\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04729387\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov55\/GEICO 91-O\/MIRASOL\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Yolanda Garc\u00eda\n                    <br>\n                    CoPI: Paula Guill\u00e9n\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator\u2019s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT-ov55\/GEICO 91-O\/MIRASOL\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04209855\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov67\/GEICO 106-O\/UPLIFT\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Alejandro P\u00e9rez Fidalgo\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 1b\/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT-ov67\/GEICO 106-O\/UPLIFT\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03319628\" target=\"_blank\">See more<\/a>\n        \n        <\/div>\n\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n                    \n            <div class=\"col-12 ovario\">\n                <span>\n                    Ovary\n                <\/span>\n                <span>\n                    Recurrence\n                <\/span>\n            <\/div>\n        \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov50\/GEICO 82-O\/INNOVATE 3\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of patients with recurrent ovarian cancer not suitable for platinum treatment (ROC-NP)\n            <\/div>\n        \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Ovario reca\u00edda\"\n                data-titulo=\"ENGOT-ov50\/GEICO 82-O\/INNOVATE 3\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n        \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03940196\" target=\"_blank\">See more<\/a>\n        \n        <\/div>        \n        \n    <\/div>\n\n    <div id=\"contenidoCervixMetastasico\" class=\"mt-3 col-12 d-flex justify-content-start flex-wrap abierto\">\n            \n\n\n        <!-- seguimiento -->\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 cervix\">\n                <span>\n                    Cervix\n                <\/span>\n                <span>\n                    Metastatic \n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-cx10\/GEICO 68-C\/BEATcc\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix \n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"C\u00e9rvix metast\u00e1sico\"\n                data-titulo=\"ENGOT-cx10\/GEICO 68-C\/BEATcc\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/search?term=NCT03556839\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <!-- reclutamiento -->\n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n            <div class=\"col-12 cervix\">\n                <span>\n                    Cervix\n                <\/span>\n                <span>\n                    Metastatic \n                <\/span>\n            <\/div>\n\n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT cx20\/GEICO 138-C\/MK2870-020\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                    <br>\n                    CoPI: Luis Manso\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice as Second-line Treatment for Participants with Recurrent or Metastatic  Cervical Cancer\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"C\u00e9rvix metast\u00e1sico\"\n                data-titulo=\"ENGOT cx20\/GEICO 138-C\/MK2870-020\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03786081?term=NCT03786081&rank=1\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n        \n    <\/div>\n\n    <div id=\"contenidoCervixAvanzado\" class=\"mt-3 col-12 d-flex justify-content-start flex-wrap abierto\">\n            \n        <!-- Start Up -->\n\n        <!--<div class=\"layout_contenidos card d-flex flex-wrap startup\">\n            <div class=\"col-12 cervix\">\n                <span>\n                    Cervix\n                <\/span>\n                <span>\n                    Locally advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-startUp\">\n                Start Up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-cx19\/GEICO 133-C\/eVolve-Cervical\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: M\u00aa Jes\u00fas Rubio\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"C\u00e9rvix Localmente Avanzado\"\n                data-titulo=\"ENGOT-cx19\/GEICO 133-C\/eVolve-Cervical\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06079671?rank=1\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap startup\">\n            <div class=\"col-12 cervix\">\n                <span>\n                    Cervix\n                <\/span>\n                <span>\n                    Locally advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-startUp\">\n                Start Up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-cx19\/GEICO133-C\/eVOLVE-Cervical\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"C\u00e9rvix Localmente Avanzado\"\n                data-titulo=\"ENGOT-cx19\/GEICO133-C\/eVOLVE-Cervical\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06079671?rank=1\" target=\"_blank\">See more<\/a>\n\n        <\/div>-->\n\n        <!-- seguimiento -->\n\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 cervix\">\n                <span>\n                    Cervix\n                <\/span>\n                <span>\n                    Locally advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 78-C\/ATOMICC\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A randomized, open label, phase II trial of Anti-PD1, dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"C\u00e9rvix Localmente Avanzado\"\n                data-titulo=\"GEICO 78-C\/ATOMICC\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03833479\" target=\"_blank\"> Ver m\u00e1s \n            <\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 cervix\">\n                <span>\n                    Cervix\n                <\/span>\n                <span>\n                    Locally advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-cx12\/GEICO 84-C\/GCT1015-07 \n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                    <br>\n                    CoPI: Jer\u00f3nimo Mart\u00ednez Garc\u00eda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator\u2019s Choice Chemotherapy in Second or Third Line Metastatic or Recurrent Cervical Cancer\u201d\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"C\u00e9rvix Localmente Avanzado\"\n                data-titulo=\"ENGOT-cx12\/GEICO 84-C\/GCT1015-07\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04221945\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 cervix\">\n                <span>\n                    Cervix\n                <\/span>\n                <span>\n                    Locally advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-cx11\/GEICO 86-C\/MK3475-A18\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer\u201d \n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"C\u00e9rvix Localmente Avanzado\"\n                data-titulo=\"ENGOT-cx11\/GEICO 86-C\/MK3475-A18\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/search?term=engot%20cx8\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 cervix\">\n                <span>\n                    Cervix\n                <\/span>\n                <span>\n                    Locally advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-cx8\/GEICO 113-C\/TV205 \n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Phase II randomized, double-blind study comparing 3-weekly carboplatin (AUC 5) + paclitaxel 175 mg\/m\u00b2, with or without concomitant and maintenance nintedanib, in patients with advanced or recurrent cervical cancer\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"C\u00e9rvix Localmente Avanzado\"\n                data-titulo=\"ENGOT-cx8\/GEICO 113-C\/TV205\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03786081?term=NCT03786081&rank=1\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        \n    <\/div>\n\n    <div id=\"contenidoEndometrioAvanzado\" class=\"mt-3 col-12 d-flex justify-content-start flex-wrap abierto\">\n            \n        <!-- reclutamiento -->\n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n\n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT en 13\/GEICO 108-E\/DOMENICA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: M\u00aa Jesus Rubio\n                    <br>\n                    CoPI: Pau Guill\u00e9n\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced\/metastatic setting)\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT en 13\/GEICO 108-E\/DOMENICA\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT05201547\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT en 20\/GEICO 124-E\/XPORT-EC-042\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Alejandro P\u00e9rez Fidalgo\n                    <br>\n                    CoPI: Lorena Fari\u00f1as\n                <\/p>\n            <\/div>\n\n            \n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A PHASE 3, Randomized, placebo-controlled, Double-Blind, multicenter Trial of selinexor in Maintenance therapy After systemic therapy for Patients with P53 Wild-TYPE, Advanced or Recurrent Endometrial carcinoma\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT en 20\/GEICO 124-E\/XPORT-EC-042\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05611931\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap reclutamiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-reclutamiento\">\n                Recruitment\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-EN26\/GEICO 150-E\/ASCENT-GYN-01\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Eva Guerra\n                    <br>\n                    CoPI: Marina Justo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            \u201cA Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician\u2019s Choice in Participants With Recurrent or Advanced Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-(L)1 Immunotherapy\u201d    <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT-EN26\/GEICO 150-E\/ASCENT-GYN-01\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06486441\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <!-- seguimiento -->\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-en23\/GEICO 132-E\/MK 2870 \n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Pilar Barretina\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT-en23\/GEICO 132-E\/MK 2870\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06132958\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-en7\/GEICO 75-E\/ATTEND\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Pilar Barretina\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced\/recurrent endometrial cancer\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT-en7\/GEICO 75-E\/ATTEND\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03603184\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <!--<div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Start UP\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-en16\/GEICO 117-R\/EXPRESSION XI\/IMPROVE\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Pilar Barretina\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                International Survey for Patients with Endometrial Cancer: Perspectives and Expectation of Therapy and Quality of Life(EXPRESSION XI\/IMPROVE)\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT-en16\/GEICO 117-R\/EXPRESSION XI\/IMPROVE\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06018337\" target=\"_blank\">See more<\/a>\n\n        <\/div>-->\n\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-en10\/GEICO 92-E\/DUO-E\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Marta Gil\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Phase 3Trial with Durvalumab-Olaparib in Newly Diagnosed Advanced and Recurrent endometrial cancer\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT-en10\/GEICO 92-E\/DUO-E\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04269200\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-en9\/GEICO 83-E\/LEAP-001 \n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: M\u00aa Jes\u00fas Rubio\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080\/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma \n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT-en9\/GEICO 83-E\/LEAP-001\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-003009-24\/DE\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-en15\/GEICO 111-E\/MK-3475-C93\u00a0 \n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ignacio Romero\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting \n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT-en15\/GEICO 111-E\/MK-3475-C93\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-003185-12\/IT\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-en6\/GEICO 93-E\/RUBY\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                    <br>\n                    CoPI: Lydia Gaba\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A phase 3, randomized, double blind multicenter study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus placebo plus Carboplatin-Paclitaxel in patients with recurrent or primary advance endometrial cancer \n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"ENGOT-en6\/GEICO 93-E\/RUBY\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03981796\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <!--<div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Advanced\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 70-E\/AVE-IIG-03\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Josep Mar\u00eda Piulats Rodr\u00edguez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Phase II multicenter, open label, single arm trial of Avelumab in combination with Pegylated Liposomal Doxorubicin in recurrent \/metastatic endometrial cancer\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio avanzado\"\n                data-titulo=\"GEICO 70-E\/AVE-IIG-03\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03981796\" target=\"_blank\">See more<\/a>\n\n        <\/div>-->\n        \n    <\/div>\n\n    <div id=\"contenidoEndometrioLocalizado\" class=\"mt-3 col-12 d-flex justify-content-start flex-wrap abierto\">\n            \n        <!-- seguimiento -->\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Localized\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-en11\/GEICO 94-E\/MK\u20103475\u2010B21\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Pilar Barretina\n                    <br>\n                    CoPI: Lorena Fari\u00f1as\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Phase 3, Randomized, Double\u2010Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High\u2010Risk Endometrial Cancer After Surgery With Curative Intent \u201c\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio localizado\"\n                data-titulo=\"ENGOT-en11\/GEICO 94-E\/MK\u20103475\u2010B21\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-003424-17\/CZ\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            \n            <div class=\"col-12 endometrio\">\n                <span>\n                    Endometrium\n                <\/span>\n                <span>\n                    Localized\n                <\/span>\n            <\/div>\n            \n            <div class=\"study-state state-seguimiento\">\n                Follow - up\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-EN2\/GEICO 47-E\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Santaballa\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer. A Phase II, multicenter, prospective, open-label, randomized, controlled study.\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Endometrio localizado\"\n                data-titulo=\"ENGOT-EN2\/GEICO 47-E\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n\n        <\/div>\n        \n    <\/div>\n\n    <div id=\"contenidoOtrosQuirurgico\" class=\"mt-3 col-12 d-flex justify-content-start flex-wrap abierto\">\n        \n        <!-- seguimiento -->\n        <div class=\"layout_contenidos card d-flex flex-wrap seguimiento\">\n            <div class=\"col-12 otros\">\n                <span>\n                    Other\n                <\/span>\n                <span>\n                    Surgical\n                <\/span>\n            <\/div>\n\n            <div class=\"study-state state-seguimiento\">\n                Fllow - up\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT cx4\/GEICO 130Q\/SENTICOL III\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ignacio Zapardiel\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                An international, prospective, randomized, multicenter, single blind trial to compare sentinel lymph node (SLN) biopsy versus SLN biopsy + pelvic lymphadenectomy in term of DFS and HR-QoL\n            <\/div>\n            \n            <a \n                class=\"col-12 mt-2 centros_hospitalarios\"\n                data-mdb-toggle=\"modal\"\n                data-mdb-target=\"#modalInvestigaciones\"\n                data-ensayo=\"Otros quirurgico\"\n                data-titulo=\"ENGOT cx4\/GEICO 130Q\/SENTICOL III\"\n                data-mdb-placement=\"top\">\n                View hospitals\n                <svg class=\"ms-2\" width=\"11\" height=\"10\" viewBox=\"0 0 11 10\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\">\n                    <path d=\"M11 5.00407C10.9962 5.44281 10.8296 5.86228 10.5364 6.17158L7.16571 9.7575C7.0185 9.91282 6.81936 10 6.61179 10C6.40421 10 6.20507 9.91282 6.05786 9.7575C5.98421 9.67997 5.92576 9.58774 5.88587 9.48612C5.84598 9.38449 5.82544 9.27549 5.82544 9.1654C5.82544 9.05532 5.84598 8.94632 5.88587 8.84469C5.92576 8.74307 5.98421 8.65084 6.05786 8.57331L8.64286 5.83801H0.785714C0.57733 5.83801 0.377481 5.75015 0.230131 5.59375C0.0827805 5.43736 0 5.22525 0 5.00407C0 4.7829 0.0827805 4.57079 0.230131 4.41439C0.377481 4.258 0.57733 4.17014 0.785714 4.17014H8.64286L6.05786 1.4265C5.9099 1.27057 5.82637 1.05865 5.82563 0.837353C5.8249 0.616056 5.90702 0.403514 6.05393 0.246481C6.20084 0.089448 6.40051 0.000787735 6.60901 5.72205e-06C6.81751 -0.000776291 7.01776 0.0863848 7.16571 0.242311L10.5364 3.82823C10.8315 4.13958 10.9982 4.56244 11 5.00407Z\" \n                    fill=\"#6BA7BD\"\/>\n                <\/svg> \n            <\/a>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03386734\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n        \n    <\/div>\n\n    <div id=\"contenidoCerradoOvario\" class=\"d-flex flex-wrap justify-content-start d-none\">\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov40\/GEICO 71-R\/Expression VI\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: P. Barretina\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Caroline meets HANNA \u2013 Holistic Analysis of LoNgterm-survival with OvariaNCAncer.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 66-O\/OLATRA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: I. Romero \n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Phase II studyofOlaparib as maintenanceTherapyafter response totrabectedin-pegylatedliposomaldoxorubicin in recurrentovarian carcinoma.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03470805\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov25\/GEICO 48-O\/PAOLA-1\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB \u2013 IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02477644\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 29-O\/INOVATION\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: A. Poveda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Phase III study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01379989\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT OV27\/GEICO 52-O\/MORAB\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Phase II study Carbo + DLP or paclitaxel with or without farletuzumabplatinum resistant relapses with low levels of CA 125.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov26\/GEICO 54-O\/PRIMA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 3 Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02655016\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 37-O\/NOVA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Y. Garc\u00eda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo cl\u00ednico fase II de quimioterapia neoadyuvante con o sin Bevacizumab en pacientes con c\u00e1ncer de ovario.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 31-O\/NOVA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: JM. Del Campo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                F III, mantenimiento con niraparib vs placebo en reca\u00edda platino sensible.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT ov21\/GEICO 39-O\/SOLO-2\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: A. Poveda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                F III Olaparib vs placebo de mantenimiento tras reca\u00edda platino-sensible.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03470805\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 30-Q\/DESKTOP III\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: A. Poveda \/ S. Mart\u00ednez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                F III cirug\u00eda o no en la reca\u00edda platino sensible.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01166737\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 33-O\/PENELOPE\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                F III QT +\/- pertuzumab en platino-resistente.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01684878\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 42-R\/ROSE\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio retrospectivo sobre tratamiento del c\u00e1ncer de ovario.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 44-R\/RETRO-ROC\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: I. Romero\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio post-autorizacio\u0301n observacional restrospectivo y multice\u0301ntrico de la combinacio\u0301n con trabectedina y doxorubicinaliposomalpegilada (DLP) en ca\u0301ncer de ovario recidivante.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02394015\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    C\u00d3DIGO DE ENSAYO CL\u00cdNICO: GEICO 1302 - ENGOT OV 11 - Array 162-311\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: I. Romero\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician\u2019s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    C\u00d3DIGO DE ENSAYO CL\u00cdNICO: GEICO 1303-ENGOT OV 16- NOVA (ENGOT)\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: JM. Del Campo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-OV-2b\/TRINOVA 3\/GEICO-1201\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: JM. Del Campo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                TRINOVA \u2013 A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    MM-121\/GEICO 1202\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez, Andr\u00e9s Redondo, JM. Rubio, A. Poveda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant\/ Refractory Advanced Ovarian Cancers.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    NCIC-OV 21\/GEICO-0902\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: I. Romero, J. Ponce\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio de Fase II-III de quimioterapia intraperitoneal (IP) m\u00e1s intravenosa (IV) frente a carboplatino m\u00e1s Paclitaxel IV en pacientes con carcinoma epitelial de ovario sometidas a cirug\u00eda citoreductora \u00f3ptima posterior a quimioterapia intravenosa neoadyuvante.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 1001-CATUMAXOMAB\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo Fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidaci\u00f3n de pacientes con un carcinoma epitelial de ovario, de trompa de Falopio, o un carcinoma primario peritoneal en segunda o tercera remisi\u00f3n completa cl\u00ednica.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    AGO-OVAR 12\/GEICO 1003\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: JM. Del Campo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio de fase III, multic\u00e9ntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinaci\u00f3n con carboplatino y paclitaxel comparado con placebo en combinaci\u00f3n con carboplatino y paclitaxel en pacientes con c\u00e1ncer de ovario avanzado.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 1002\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo cl\u00ednico fase II no controlado, multic\u00e9ntrico y prospectivo para determinar el beneficio cl\u00ednico y toxicidad de Pazopanib, inhibidor multidiana de receptores con actividad tirosin-quinasa (VEGFR -1, -2 , -3, PDGFR-\u03b1 y \u03b2 y C-Kit), en pacientes con c\u00e1ncer de ovario avanzado platino resistentes.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ICON-6\/GEICO 1101\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo cl\u00ednico multic\u00e9ntrico del Gynaecologic Cancer Intergroup, controlado doble ciego de Cediranib (AZD 2171), en combinaci\u00f3n con quimioterapia basada en platino y como agente \u00fanico en terapia de mantenimiento, en mujeres con c\u00e1ncer de ovario que han reca\u00eddo m\u00e1s de 6 meses tras la finalizaci\u00f3n de un tratamiento de primera l\u00ednea basado en platino.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    AURELIA\/GEICO 0904\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: A. Poveda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                AURELIA: Ensayo cl\u00ednico de fase III multic\u00e9ntrico, abierto, aleatorizado, con dos grupos de tratamiento, de bevacizumab en combinaci\u00f3n con quimioterapia frente a quimioterapia sola en pacientes con c\u00e1ncer epitelial de ovario, carcinoma de trompas de Falopio o peritoneal primario resistente a platino.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0901\/AGO-OVAR 16\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: JM del Campo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio de fase III para evaluar la eficacia y la seguridad de pazopanib en monoterapia frente a placebo entre mujeres con c\u00e1ncer epitelial de ovario, de trompa de Falopio o peritoneal primario que no hayan progresado despu\u00e9s de la quimioterapia de primera l\u00ednea.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0905-OCTAVIA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A single-arm Phase II clinical study of the combination of carboplatin and weekly periclitar plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0802\/HECTOR-PHASE III-2006\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez, A. Santaballa\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Topotec\u00e1n m\u00e1s carboplatino frente al tratamiento est\u00e1ndar (paclitaxel m\u00e1s carboplatino o gemcitabina m\u00e1s carboplatino) en el tratamiento de pacientes con carcinoma peritoneal, carcinoma de trompas o carcinoma epitelial de ovario plantino-sensibles recidivantes.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0804-R\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: B. Ojeda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Base de datos de Bevacizumab en reca\u00eddas de C\u00e1ncer de Ovario.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0801-T\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: A. Poveda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio retrospectivo de biomarcadores en C\u00e1ncer Epitelial de Ovario.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0803-R\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin \n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Feasibility and toxicity of a modified outpatient regimen of intravenous\/ intraperitoneal chemotherapy (IV\/IP) in optimally debulked stage III ovarian cancer patients: A GEICO Study.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0701\/ICON-7\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: A. Cervantes\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio aleatorizado del \u201cGynaecologic Cancer InterGroup\u201d, de dos grupos, multic\u00e9ntrico para a\u00f1adir bevacizumab a la quimioterapia est\u00e1ndar (carboplatino y paclitaxel) en pacientes que sufren c\u00e1ncer epitelial de ovario.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0702-T\/TOPO IIA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Determinaci\u00f3n de la expresi\u00f3n de TOPO IIA en muestras de carcinoma de ovario de pacientes tratadas con doxorubicina liposomal pegilada.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0703\/MIMOSA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: A. Casado\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo cl\u00ednico multic\u00e9ntrico aleatorizado, doble ciego, controlado con placebo, para evaluar el tratamiento de mantenimiento con abagovomab en pacientes afectas de carcinoma epitelial ov\u00e1rico tras respuesta completa a la quimioterapia de la 1\u00aa l\u00ednea.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0104\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio fase II randomizado del doblete carboplatino-gemcitabina seguido de carboplatino paclitaxel versus carboplatino-paclitaxel en pacientes con recidiva platinosensible de carcinoma de ovario, carcinomatosis peritoneal primaria o carcinoma de trompa.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0101\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: MA. Izquierdo, A. Cervantes\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo cl\u00ednico de fase III para evaluar el tratamiento con la combinaci\u00f3n cisplatino m\u00e1s topotec\u00e1n seguido de paclitaxel m\u00e1s carboplatino frente a paclitaxel m\u00e1s carboplatino como tratamiento de primera l\u00ednea en mujeres con un diagn\u00f3stico reciente de c\u00e1ncer epitelial de ovario avanzado.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0103\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: B. Ojeda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio fase II, con Gemcitabina en infusi\u00f3n prolongada en pacientes con c\u00e1ncer epitelial de ovario avanzado resistentes a platino\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO CO22\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: A. Casado\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Validaci\u00f3n por GEICO de CAELYX en pacientes con c\u00e1ncer epitelial de ovario.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0199\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo cl\u00ednico fase II randomizado (con valoraci\u00f3n de calidad de vida) de carboplatino frente a la combinaci\u00f3n de taxol y carboplatino en pacientes con reca\u00edda de c\u00e1ncer de ovario platino-sensible.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 0299\/EORTC 55981\/NSGO\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: MA. Izquierdo, JM del Campo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo Cl\u00ednico aleatorizado de Paclitaxel \/ Epirubicina \/ Carboplatino en combinaci\u00f3n (TEC) vs Paclitaxel \/ Carboplatino (TC) en el tratamiento de mujeres con c\u00e1ncer de ovario avanzado.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <!--<div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT OV68\/GEICO 112-O\/ARTISTRY 7\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Andr\u00e9s Redondo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator\u2019s Choice Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05092360\" target=\"_blank\">See more<\/a>\n\n        <\/div>-->\n\n        <!-- nuevos -->\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov60\/GEICO 98-O\/Ramp 201\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                    <br>\n                    CoPI: Alejandro P\u00e9rez Fidalgo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 2 Study of VS-6766 (Dual RAF\/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03740165\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov66\/GEICO 104-O\/AXLerate-OC \n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                    <br>\n                    CoPI: Pilar Barretina\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Phase 3, Randomized, Double-Blind, Adaptive, Placebo\/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT04729608\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                GEICO 55-O\/ROLANDO \n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Alejandro P\u00e9rez Fidalgo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Multicentric Single arm Phase II clinical trial, to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma, and fallopian tube cancer patients\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03161132\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov20\/GEICO 30-Q\/DESKTOP III\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Andr\u00e9s Poveda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01166737\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov11\/GEICO 40-O\/MILO\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ignacio Romero\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Randomized Phase III MEK152 vs chemo Low Grade Serous Ovarian Cancer\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02101788\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov38\/GEICO 62-O\/OReO \n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Andr\u00e9s Redondo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)\n            <\/div>\n\n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03106987\" target=\"_blank\">See more<\/a>\n\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov21\/GEICO 39-O\/SOLO-2\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Andr\u00e9s Poveda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01874353\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                GEICO 105-O\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: M\u00aa Jes\u00fas Rubio\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study\n            <\/div>\n\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov25\/GEICO 48-O\/PAOLA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez \/ Ra\u00fal Marquez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB \u2013 IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance\n            <\/div>\n\n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02477644\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <!-- cuando quite estilos clase cerrado  cambiar xxx por cerrado-->\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n\n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov39\/GEICO 63-O\/IMAGYN 050\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Yolanda Garc\u00eda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase III study of Atezolizumab versus Placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with new diagnosed stage III\/stage IV Ovarian, Fallopian Tube or Primary Peritoneal Cancer.\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03038100\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <!-- cuando quite estilos clase cerrado  cambiar por cerrado-->\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n\n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov26\/GEICO 54-O\/PRIMA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02655016\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <!-- cuando quite estilos clase cerrado  cambiar por cerrado-->\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-ov29\/GEICO 58-O\/ATALANTE\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab.\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02891824\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <!-- cancelados -->\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cancelados\">\n            \n            <div class=\"col-12 cancelado\">\n                <span>\n                    Cancelled\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov73\/GEICO 123-O\/LUPPA-1\n\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                    <br>\n                    CoPI: Luis Manso\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin in Combination with Paclitaxel vs. Platinum-based Chemotherapy or Weekly Paclitaxel as Treatment in Patients with Relapsed Platinum-sensitive Ovarian Cancer \n            <\/div>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cancelados\">\n            \n            <div class=\"col-12 cancelado\">\n                <span>\n                    Cancelled\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-ov71\/GEICO 121-O\/UP-NEXT \n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                    <br>\n                    CoPI: Marga Romero\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants with Recurrent, Platinum-Sensitive, High-grade Serous Ovarian Cancer \n            <\/div>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cancelados\">\n            \n            <div class=\"col-12 cancelado\">\n                <span>\n                    Cancelled\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT OV75\/ GEICO 128-O\/INNOVATE 5\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Margarita Romero Mart\u00edn\n                    <br>\n                    CoPI: Gloria Marquina\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A Pivotal, Randomized Controlled, Open-Label Study of Tumor Treating Fields (TT Fields) in Patients with Recurrent Ovarian Cancer in Whom Platinum Is an Option\n            <\/div>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cancelados\">\n            \n            <div class=\"col-12 cancelado\">\n                <span>\n                    Cancelled\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT gyn2\/GEICO 97-O\/BOUQUET\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Andr\u00e9s Redondo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A phase II, open-label, multicenter, platform study evaluating the efficacy and safety of biomarker-driven therapies in patients with persistent or recurrent rare epithelial ovarian tumors.\n            <\/div>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cancelados\">\n                    \n            <div class=\"col-12 cancelado\">\n                <span>\n                    Cancelled\n                <\/span>\n                <span>\n                    Ovarian cancer\n                <\/span>\n            <\/div>\n        \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT ov79\/GEICO 134-O\/STRO-002-GM3 (REFRaME-01)\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n        \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 2\/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator\u2019s Choice of Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)\n            <\/div>\n  \n        <\/div>\n\n    <\/div>\n\n    <div id=\"contenidoCerradoCervix\" class=\"d-flex flex-wrap justify-content-start d-none\">\n            \n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Cervical cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-Cx6\/GEICO 73-C\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Antonio Gonz\u00e1lez\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A Phase 2 Trial of TisotumabVedotin (HuMax\u00ae-TF- ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Cervical cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-CX1\/GEICO 43-O\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: MJ Rubio\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n                Estudio de fase II, de tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg\/m2de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante.\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02009579\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Cervical cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 61-C\/AIM2CERV\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Phase 3 of ADX11-001 administered following chemoradiation as adjuvant treatment for HRLACC.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02853604\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Cervical cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 46-O\/CECILIA\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Andr\u00e9s Redondo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Fase II carbo-paclitaxel-bevacizumab en primera l\u00ednea del carcinoma de c\u00e9rvix persistente, recurrente o diseminado.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Cervical cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GOG-0240 \/ GEICO-0903\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo en Fase III aleatorizado de Cisplatino m\u00e1s Paclitaxel con y sin Bevacizumab frente al doblete sin platino, Topotecan m\u00e1s Paclitaxel, con y sin Bevacizumab, en carcinoma de c\u00e9rvix en estadio IVB, recurrente o persistente.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Cervical cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 2005\/01\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: MJ Rubio\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Estudio exploratorio fase II para evaluar la eficacia y seguridad de topotecan semanal en el tratamiento de Cervical cancer persistente o recidivante tras fracaso de tratamiento de primera l\u00ednea con derivados del platino.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Cervical cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-cx9\/GEICO 72-C\/EMPOWER Cx-1 \/\/ REGENERON\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Ana Oaknin\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Randomized, open-label, phase III clinical trial of REGN2810 compared to investigator's choice chemotherapy treatment for recurrent or metastatic platinum-resistant cervical carcinoma\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT03257267\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Cervical cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-cx1\/GEICO 43-C\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: M\u00aa. Jes\u00fas Rubio\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            Estudio de fase II, aleatorizado y doble ciego que compara el tratamiento cada 3 semanas con carboplatino (AUC 5) + 175 mg\/m2 de paclitaxel, con o sin nintedanib concomitante y de mantenimiento, en el carcinoma de cuello uterino avanzado o recidivante \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02009579?term=cx1&rank=1\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n\n    <\/div>\n\n    <div id=\"contenidoCerradoEndometrio\" class=\"d-flex flex-wrap justify-content-start d-none\">\n\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Endometrial cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    ENGOT-EN3\/GEICO 64-E\/PALEO\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: C. Mendiola\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02730429\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Endometrial cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO 59-RT\/Retro LMS\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: MJ Rubio\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Yondelis en leiomiosarcoma uterino: estudio retrospectivo + biomarcadores.\n            <\/div>\n            \n            <div class=\"col-12 mt-2 centros_estudios\">\n            \n            <\/div>\n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT01244789\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n        \n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Endometrial cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                    GEICO P02868\/GEIS 7\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Andr\u00e9s Poveda\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                Ensayo Fase IV-II de Temozolamida en esquema de administraci\u00f3n oral continua en el tratamiento de los Sarcomas Ginecol\u00f3gicos.\n            <\/div>\n            \n            \n            <!--<a class=\"verMas\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT02730429\" target=\"_blank\">See more<\/a>-->\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Endometrial cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                ENGOT-en5\/GEICO 67-E\/SIENDO\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Alejandro P\u00e9rez Fidalgo\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n            A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT05611931\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n\n        <div class=\"layout_contenidos card d-flex flex-wrap e-cerrados\">\n            \n            <div class=\"col-12 cerrado\">\n                <span>\n                    Closed\n                <\/span>\n                <span>\n                    Endometrial cancer\n                <\/span>\n            <\/div>\n            \n            <div class=\"col-12 mt-2\">\n                <span class=\"titulos_estudios\">\n                GEICO 70-E\/WI 231461 AVE-IIG-03\n                <\/span>\n                <p class=\"autor_estudios\">\n                    PI: Jose M\u00aa Piulats\n                <\/p>\n            <\/div>\n            \n            <div class=\"col-12 mt-2 descripcion_estudios\">\n                A PHASE II MULTICENTER, OPEN-LABEL, SINGLE ARM TRIAL OF AVELUMAB IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN IN RECURRENT\/METASTATIC ENDOMETRIAL CANCER\n            <\/div>\n            \n            <a class=\"verMas\" href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT05611931\" target=\"_blank\">See more<\/a>\n\n        <\/div>\n        \n\n    <\/div>\n\n\n    \n<\/div>\n\n<div class=\"modal fade\" id=\"modalInvestigaciones\" data-mdb-keyboard=\"false\"\n    tabindex=\"-1\" aria-labelledby=\"\" aria-hidden=\"true\">\n\n    <div class=\"modal-dialog modal-xl modal-dialog-centered\">\n    \n        <div class=\"modal-content\">\n            \n            <div class=\"modal-header\">\n                <h5 id=\"title_modal_investigaciones\" class=\"modal-title text-uppercase font fs-6\"><\/h5>\n                <button type=\"button\" class=\"btn-close\" data-mdb-dismiss=\"modal\" aria-label=\"Close\"><\/button>\n            <\/div>\n            \n            <div id=\"body_modal_investigaciones\" class=\"modal-body w-100 d-flex flex-wrap p-3\"><\/div>\n            \n            <div class=\"modal-footer modal-centered\">\n                <button id=\"boton_cerrar_investigaciones\" type=\"button\" class=\"btn\" data-mdb-dismiss=\"modal\">Close<\/button>\n            <\/div>\n        \n        <\/div>\n    <\/div>\n\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Clinical Trials Open Recruitment Follow &#8211; up Ovary First-line Recurrence Cervix Locally advanced cervix Metastatic cervix Endometrium Localized Advanced Other Surgical Closed | Cancelled Closed Cancelled Ovarian cancer Cervical cancer Endometrial cancer Ovary First &#8211; line Recruitment ENGOT-ov62\/GEICO 129-O\/N-Plus PI: Purificaci\u00f3n Estevez CoPI: Arantzazu Barquin A Phase III randomized, open label study of NiraParib maintenance &#8230; <a title=\"Clinical Trials\" class=\"read-more\" href=\"https:\/\/www.geicogroup.com\/en\/research\/clinical-trials\/\" aria-label=\"More on Clinical Trials\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":9853,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-profesional.php","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-9855","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/comments?post=9855"}],"version-history":[{"count":18,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9855\/revisions"}],"predecessor-version":[{"id":10293,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9855\/revisions\/10293"}],"up":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9853"}],"wp:attachment":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/media?parent=9855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}